Bicycle Therapeutics Files 8-K on Security Holder Vote Matters
Ticker: BCYC · Form: 8-K · Filed: May 16, 2024 · CIK: 1761612
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
Related Tickers: BCYC
TL;DR
BCYC shareholders voting on key company matters. Stay tuned.
AI Summary
On May 16, 2024, Bicycle Therapeutics plc filed an 8-K report indicating a submission of matters to a vote of security holders. The company, incorporated in England and Wales, is based in Cambridge, UK, with its principal executive offices at Blocks A & B, Portway Building, Granta Park, Great Abington, CB21 6GS.
Why It Matters
This filing signals that Bicycle Therapeutics is engaging its shareholders on important company decisions, which could impact future strategic direction and shareholder value.
Risk Assessment
Risk Level: low — The filing is procedural, reporting on a vote of security holders, and does not disclose new financial or operational risks.
Key Players & Entities
- Bicycle Therapeutics plc (company) — Registrant
- England and Wales (jurisdiction) — Place of incorporation
- May 16, 2024 (date) — Date of report
- Blocks A & B, Portway Building, Granta Park Great Abington, Cambridge United Kingdom CB21 6GS (address) — Principal executive offices
FAQ
What specific matters are being submitted for a vote of security holders?
The filing does not specify the exact matters to be voted on, only that such matters are being submitted.
When is the meeting or vote expected to take place?
The filing does not provide a date for the meeting or vote.
What is the company's primary business?
Bicycle Therapeutics plc is in the Pharmaceutical Preparations industry (SIC code 2834).
Where is Bicycle Therapeutics plc headquartered?
The company is headquartered in Cambridge, United Kingdom, at Blocks A & B, Portway Building, Granta Park, Great Abington, CB21 6GS.
What is the SEC file number for this filing?
The SEC file number is 001-38916.
Filing Stats: 1,002 words · 4 min read · ~3 pages · Grade level 13.2 · Accepted 2024-05-16 16:01:29
Filing Documents
- tm2414682d1_8k.htm (8-K) — 59KB
- 0001104659-24-062503.txt ( ) — 278KB
- bcyc-20240516.xsd (EX-101.SCH) — 3KB
- bcyc-20240516_def.xml (EX-101.DEF) — 26KB
- bcyc-20240516_lab.xml (EX-101.LAB) — 36KB
- bcyc-20240516_pre.xml (EX-101.PRE) — 25KB
- tm2414682d1_8k_htm.xml (XML) — 6KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders Bicycle Therapeutics plc (the "Company") held its annual general meeting of shareholders (the "AGM") on May 16, 2024. Each of the proposals set forth below were voted on and duly passed on a poll at the AGM. Detailed descriptions of these proposals and of the voting procedures applied at the AGM are contained in the Company's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 15, 2024. There were 37,398,107 ordinary shares of the Company represented in person or by proxy at the AGM, constituting approximately 98.19% of the issued and outstanding ordinary shares on May 16, 2024. Proxy appointments which gave the Chairman of the meeting discretion have been included in the "For" total. In accordance with the terms of the deposit agreement by and among the Company, Citibank, N.A. as depositary and holders and beneficial owners of American Depositary Shares ("ADSs") dated May 28, 2019, holders of ADSs who did not provide the depositary bank with voting instructions on or before the specified deadline were deemed to have instructed the depositary to give a discretionary proxy to a person designated by the Company to vote the underlying ordinary shares at the AGM and the voting results below reflect that designation. A vote withheld/abstain is not a vote in law and is not counted in the calculation of votes for or against a resolution. Ordinary Resolutions Proposal 1 – To re-elect as a director Kevin Lee. For Against Vote Withheld/Abstain 36,413,260 977,286 7,561 Proposal 2 – To re-elect as a director Jose-Carlos Gutierrez-Ramos. For Against Vote Withheld/Abstain 35,019,069 2,371,385 7,653 Proposal 3 – To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's definitive proxy statement. For Against Vote Withheld/Abstain 36,186,115 1,202,477 9,515 Proposal 4 – T
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 16, 2024 BICYCLE THERAPEUTICS PLC By: /s/ Alethia Young Name: Alethia Young Title: Chief Financial Officer